Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Apr;62(1):26-33.
doi: 10.1016/j.critrevonc.2006.12.003. Epub 2007 Jan 19.

FcgammaR: The key to optimize therapeutic antibodies?

Affiliations
Review

FcgammaR: The key to optimize therapeutic antibodies?

Sophie Sibéril et al. Crit Rev Oncol Hematol. 2007 Apr.

Abstract

The binding of IgG to receptors for the Fc region of IgG (FcgammaR) is a critical step for the initiation and the control of effector immune functions. Activating FcgammaR induce antibody-dependent cell cytotoxicity (ADCC), endocytosis of immune complexes followed by antigen presentation, phagocytosis, and release of cytokines or pro-inflammatory mediators. By contrast, inhibitory FcgammaR regulate immune responses by inhibiting the activation of B lymphocytes, monocytes, mast cells and basophils, induced through activating receptors. Studies with FcgammaR-deficient mice support the critical role of the different FcgammaR in the in vivo functional effects of therapeutic monoclonal antibodies. Structural studies have provided detailed insights in the molecular mechanisms that govern IgG/FcgammaR interactions. The importance of the sugar components linked to asparagine 297 in the function of IgG has been also highlighted. These data have led to the engineering of a new generation of monoclonal antibodies for therapeutic use with optimized effector functions.

PubMed Disclaimer

Comment in

  • "Antibodies in cancer treatment".
    Desoize B. Desoize B. Crit Rev Oncol Hematol. 2007 Apr;62(1):23-5. doi: 10.1016/j.critrevonc.2007.02.004. Crit Rev Oncol Hematol. 2007. PMID: 17338979 No abstract available.

Similar articles

Cited by

Publication types

LinkOut - more resources